Information Provided By: 
Fly News Breaks for February 9, 2018
ALNY
Feb 9, 2018 | 07:26 EDT
Nomura Instinet analyst Christopher Marai raised his price target for Alnylam Pharmaceuticals to $86 citing the earnings results, restructuring of deal terms with Sanofi, as well as revised revenue estimates based on a broader label. The analyst, however, still anticipates the company's cash burn will continue to increase, only partially offset by the patisiran launch. He expects "yet another financing." Marai reiterates a Reduce rating on Alnylam and continues to recommend taking profits in the shares.
News For ALNY From the Last 2 Days
There are no results for your query ALNY
